Development and preclinical characterization of meningococcal outer membrane vesicle vaccine
| buir.advisor | Gürsel, İhsan | |
| dc.contributor.author | Özsürekci, Yasemin | |
| dc.date.accessioned | 2024-03-20T13:29:03Z | |
| dc.date.available | 2024-03-20T13:29:03Z | |
| dc.date.copyright | 2024-03 | |
| dc.date.issued | 2024-03 | |
| dc.date.submitted | 2024-03-19 | |
| dc.department | Department of Molecular Biology and Genetics | |
| dc.description | Cataloged from PDF version of article. | |
| dc.description | Includes bibliographical references. | |
| dc.description | Thesis (Ph.D.): Bilkent University, Department of Molecular Biology and Genetics, İhsan Doğramacı Bilkent University, 2024. | |
| dc.description.abstract | Invasive meningococcal disease (IMD) is caused by Neisseria meningitidis, with the main serogroups responsible for the disease being A, B, C, W, X and Y. To date, several vaccines targeting N.meningitidis have been developed albeit with a short-lived protection. Given that MenW and MenB are the most common causes of IMD in Europe, Turkey, and Middle East, we aimed to develop an outer membrane vesicle (OMV) based bivalent vaccine as the heterologous antigen source. Herein, we compared the immunogenicity, and breadth of serum bactericidal assays (SBA) based protective coverage of OMV vaccine to X serotype with existing commercial meningococcal conjugate and polysaccharide (PS) vaccines in a murine model. BALB/c mice were immunized with preclinical batches of the W+B OMV vaccine, either adjuvanted with Alum, CpG ODN or their combinations and compared with a MenACYW conjugate vaccine (NimenrixTM, Pfizer) and a MenB OMV-based vaccine (Bexsero®, GSK). The immune responses were assessed through ELISA and SBA. Antibody responses and SBA titers were significantly higher in the W+B OMV vaccine when adjuvanted with Alum or CpG ODN, as compared to the control groups. Moreover, the SBA titers were not only significantly higher than those achieved with available conjugated ACYW vaccines but also on par with the 4CMenB vaccines. In conclusion, the W+B OMV vaccine demonstrated the capacity to elicit robust antibody responses, surpassing or matching the levels induced by licensed meningococcal vaccines. Consequently, the W+B OMV vaccine could potentially serve as a viable alternative or supplement to existing meningococcal vaccines. | |
| dc.description.degree | Ph.D. | |
| dc.description.statementofresponsibility | by Yasemin Özsürekci | |
| dc.format.extent | xii, 60 leaves [54] unnumbered leaves of plates : color illustrations, charts, maps ; 30 cm. | |
| dc.identifier.itemid | B155317 | |
| dc.identifier.uri | https://hdl.handle.net/11693/115019 | |
| dc.language.iso | English | |
| dc.publisher | Bilkent University | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Vaccination | |
| dc.subject | Adjuvant | |
| dc.subject | Meningitis | |
| dc.subject | Outer membrane vesicle | |
| dc.subject | N. meningitidis | |
| dc.subject | Men B | |
| dc.subject | Men W serotypes | |
| dc.title | Development and preclinical characterization of meningococcal outer membrane vesicle vaccine | |
| dc.title.alternative | Meningokokkal dış membran vezikül aşısının geliştirilmesi ve preklinik karakterizasyonu | |
| dc.type | Thesis |